PHARMA NEWS, MULTICHANNEL & CROSSCHANNEL MAKETING
320.8K views | +2 today
Follow

Pharma's social media activity is up, but there's still work to be done on audience insights: Review | FiercePharma

From www.fiercepharma.com

The good news is that pharma is solidly onboard with social media use. The not-as-good news is that most companies still have ground to cover in understanding their social media audiences, according to new findings from Ogilvy Healthworld, part of Ogilvy CommonHealth.
No comment yet.

Pharma Gets Social: Eight years of Twitter for Pharma – From Birth to Adolescence

From engagementstrategy.com

March 2014 marks Twitter’s 8th birthday; eight years since the social media channel’s founder Jack Dorsey sent his first tweet in 2006. At the time, few people would have imagined that this new sha...
No comment yet.

Chats not charts: a three step programme for pharmaceutical postmarketing

From stwem.com

The air of despondency that is descending over the pharmaceutical industry’s use of social media is perverse.

It has nothing to do with a putative (and also fictive) absence of interest on the patient’s part in connecting with the pharmaceutical industry.

The pharmaceutical industry’s reluctance to utilise social media outside the anodyne contexts of corporate communications is in my opinion ‘perverse’ in its primary sense: it manifests a wilful determination on pharma’s part not to do what is expected or desired of it by patients.

A new agenda

Let’s begin by assuming all drugs in any given disease area are equally efficacious, have the same characteristics, and cost the same.

That is, of course, enough to send any pharmaceutical marketer into a swoon.

They live demonstrate that this is not the case. Or, rather, they lived, past tense, to do so.

However, in social environments (among others) this is the actually-existing state of affairs.

Why? Because in contexts where promotion (i.e. head-to-head studies) is not allowed, pharmaceutical companies must look to other factors to distinguish themselves from their competitors.

Being a visible, reliable, trustworthy participant in conversations on the social web is an ideal place to demonstrate this – and it is possible.

A three point programme to effective pharmaceutical participation in social environments

  1. Be prepared – ensure all colleagues who need to know what you are going to do are aware of and comfortable with your intentions. Do not let your original plan be derailed or diluted, but make your launch plans conservative enough to ensure that you get to the starting line. Focus on building confidence: your biggest challenge will be carrying your plan forward. Drive simplicity through everything you do. Confront challenges as they arise, don’t kick them into the long grass where they will trip you up later. Write a playbook detailing what you’re going to do, where you’re going to do it, and who is going to be doing it. Cover all adverse event and product complaint requirements. Be aware of the fact that you will need to diplomatically serve and correct many educational needs internally around what will and will not happen.
  2. Be candid - be prepared to answer questions from the public as to who you are, what you’re doing, and why you’re doing it. Make a virtue of this.
  3. Be relevant – create distinctive suites of accounts for the disease areas you work in. You’re a pharmaceutical marketer. Be creative. Avoid anything which is or could be construed to be promotional. You’re a pharmaceutical marketer. You know what approvable looks like. Publish appropriate high quality, reliable, relevant information focusing on disease awareness and management. You’re a pharmaceutical marketer. You know where to find this stuff: what’s interesting, and what isn’t; what will reflect well on you indirectly, and what you need to avoid. Reach out to, connect and converse with advocates, healthcare professionals, and societies of interest in your disease area. You’re a pharmaceutical marketer. You know where to find them.

Is it really as easy as this?

Honestly? Yes, and no.

You’ll need to be able to discern and avoid the bumps in the road you will encounter, but such insights only come from experience, and in order to acquire experience, you need to be an active practitioner.

It’s time to start being one.

rob halkes's curator insight, April 1, 2014 4:53 AM

Indeed, a must read to the health industry, not just pharma. Andrew stimulates to be as brave to take the journey into practice. Several aspects will come up, but the main thing is to put it through. 


Engaging Patients Through Social Media | IMS Institute

From www.imshealth.com

IMS's Top 10 Pharma Social Media Engagers

By Ben Comer | Published: January 21, 2014

The IMS Institute for Healthcare Informatics worked up a methodology for assessing the effectiveness of pharma’s social media efforts across Facebook, Twitter and YouTube, according to three indices: reach (total number of people reached through each channel via likes, shares and re-tweets); relevance (extent to which content is being shared and forwarded); and relationship (amount of back and forth between company and patient).

Those pharmas hitting the trifecta scored best on the cumulative “Social Media Engagement Index.” Results were tallied over a two-year period. Here are the top ten pharma engagers, per IMS Health. To read the full report, which discusses the role of Wikipedia, healthcare professionals’ use of social media, and a summary of social media regulatory policy in the US, Canada and the EU, click here. And the winners are:

 

IMS Health Social Engagement Index

1. Johnson & Johnson

2. GlaxoSmithKline

3.Novo Nordisk

4. Pfizer

5. Novartis

6. Boehringer Ingelheim

7. Bayer

8. Merck

9. AstraZeneca

10. UCB

In a separate article, consultants at Capgemini Consulting Life Sciences wonder if social media in pharma has reached a tipping point. PharmExec’s sibling company, CBI, is hosting its annual iPharma conference in New York City this May.

rob halkes's curator insight, February 3, 2014 10:12 AM

It says that the self evident suspects have done the trick of social media again. What has it brought to them, besides being positioned in these lists. Has thier image raised for patients and physicians, the public in gerenal? I guess they know it, but we don't see publications of it. Do we?

Indeed there's a tipping point reached in what a pharma company may reach in doing social media in their engagement to the public in general. Now there's the time to develop their information (and promotion) channel in to interactive channels, producing support and collaboration to improve patient care. That is however, a much more challenging demand than using just social media with a multichannel mix. It depends upon their strategic starting point of what pharma wants to do for its commercial development. Now is the move to upper management  ;-)

Social Media & Cancer Drugs: Conversation, not Promotion

From www.xconomy.com

Social media hasn’t yet changed the world for biotech and pharma companies, but I believe this year is the year that will change. For better or worse, thes
No comment yet.

Tablet detailing - PMLiVE

From www.pmlive.com

t's taken a while for our industry to get on board, but it appears that tablet detailing has finally arrived. One in three details is conducted via an iPad or similar device, according to Hall & Partners research, and of our clients that have yet to embrace this evolution most say they plan to do so soon. ..

However, how much thought are we giving to this new technology? Often we hear that the edict has come from 'on high' … “We are going digital!” our clients tell us. But when we sit down to consider what this really means, conversations are often focused on the format and execution, rather than the potential for interaction offered by the new detailing medium. 

This approach sells tablet detailing short. Tablet details are visually appealing and novel, they hold vast amounts of data and offer the potential for animation and video. All good stuff, but they also provide the perfect tool to deepen customer relationships. ..

we often see that the approach to sales interactions via tablet detailing hasn't kept pace with this new reality. In 2014 we should be looking to change this.
Meeting customer expectations
Our research shows that customers have increased expectations of a tablet detail - associating the medium with innovation and interactivity. However, customer experiences of tablet detailing reveal it is perceived to offer no benefit over paper-based detailing in eliciting interest in the brand or encouraging follow-up with the rep. Pharmaceutical industry marketers and communications agencies tell a similar story of paper-based details all too often simply converted to tablet format, overlooking the opportunity the tablet provides to allow us to achieve so much more in our customer interactions...

So far we are only scratching the surface of what tablets offer in building a more holistic picture of our customers....


rob halkes's curator insight, January 28, 2014 8:00 AM

Indeed, we have seen nothing yet. In my oerceotion: pharmaceutical companies are still wrestling what or what not to do with tablets.

This is a matter of sketching your development path to a richer and more rewarding use of tablets, also in looping back information you want, can deal with and will not frustrate your customers, while they didn't hear about you anymore ;-)

See my vision it here: http://bit.ly/11n2G9d

If you need a workshop to create this path of development for you, look here: http://bit.ly/19p3S25

You're welcome to inform to me specifically, for a tailored worskhop to your needs!